The HPA Axis in PTSD: CRF, ACTH, Cortisol Dysregulation
Stress and Trauma Peptides
41 amino acids
CRF, the 41-amino-acid peptide that launches the stress response, is chronically overproduced in the brains of people with PTSD, yet their cortisol levels run paradoxically low.
Sukhareva, Vavilov Journal of Genetics and Breeding, 2021
Sukhareva, Vavilov Journal of Genetics and Breeding, 2021
View as imageThe hypothalamic-pituitary-adrenal axis is a three-organ peptide cascade that converts perceived threat into a body-wide stress response. Corticotropin-releasing factor (CRF), a 41-amino-acid peptide released by the hypothalamus, triggers ACTH release from the pituitary, which in turn drives cortisol production from the adrenal glands. In healthy people, the system activates under threat and shuts down when the threat passes. In PTSD, the system never fully resets. Understanding this cascade is central to understanding how trauma rewires peptide signaling and why peptide-based approaches to stress and aggression are drawing research attention.
The HPA axis in PTSD does not simply run too high or too low. It runs differently. The paradox that defines PTSD neuroendocrinology is that CRF is elevated in the brain while cortisol is often low in the blood. That mismatch has redirected decades of research and explains why CRF receptor antagonists, despite strong preclinical rationale, have failed in human clinical trials.
Key Takeaways
- CRF, the 41-amino-acid hypothalamic peptide that initiates the stress response, is chronically overproduced in the cerebrospinal fluid of PTSD patients[1]
- PTSD is characterized by the "low cortisol paradox": basal cortisol is reduced despite chronic stress, likely due to enhanced glucocorticoid receptor sensitivity[2]
- CRF1 receptor antagonist GSK561679 failed Phase II trials in women with PTSD, showing no superiority over placebo
- Neuropeptide Y (NPY) is associated with stress resilience, and intranasal NPY is being studied as a PTSD intervention[3]
- CRF and urocortins modulate serotonin release from the raphe nuclei, providing a mechanism linking HPA axis dysfunction to mood disorders[4]
- NPY and CRF interact at the subcellular level in the central amygdala, the brain region most directly tied to fear processing[5]
The HPA Axis: A Peptide Cascade
The HPA axis operates as a sequential peptide signaling chain. When the brain detects a threat, neurons in the paraventricular nucleus (PVN) of the hypothalamus release CRF into the hypophyseal portal system, a network of blood vessels connecting the hypothalamus to the anterior pituitary gland.
CRF binds to CRF1 receptors on corticotroph cells in the anterior pituitary. This triggers cleavage of pro-opiomelanocortin (POMC), a 241-amino-acid precursor peptide, into adrenocorticotropic hormone (ACTH) and other peptide fragments including beta-endorphin. ACTH enters the general circulation and reaches the adrenal cortex, where it stimulates cortisol synthesis and release.
Cortisol acts throughout the body to mobilize energy, suppress inflammation, and shift the immune system. It also feeds back to the hypothalamus and pituitary to suppress further CRF and ACTH release. This negative feedback loop normally limits the stress response to a finite duration.
Sukhareva (2021) reviewed the role of CRF and its receptor subtypes (CRF1 and CRF2) in regulating the stress response, noting that the two receptor types have distinct and sometimes opposing functions. CRF1 activation drives anxiety-like behavior and HPA axis activation, while CRF2 activation, primarily by the related peptides urocortin 2 and urocortin 3, promotes stress recovery and anxiolysis.[1]
What Goes Wrong in PTSD
PTSD disrupts the HPA axis at multiple levels simultaneously. The dysfunction is not a simple case of the system being stuck in the "on" position.
Elevated CRF in the brain
Cerebrospinal fluid (CSF) studies consistently find elevated CRF concentrations in PTSD patients compared to healthy controls and even compared to patients with other psychiatric conditions. The hypothalamus continues to overproduce CRF even in the absence of an acute threat, as though the threat detection system has been permanently recalibrated.
Vasconcelos et al. (2020) reviewed CRF receptor signaling and modulation in the context of stress response and resilience. They noted that CRF acts not only through the classical HPA axis pathway but also through extrahypothalamic circuits in the amygdala, bed nucleus of the stria terminalis, and locus coeruleus, where it directly drives anxiety, hypervigilance, and startle responses independent of cortisol.[2]
The low cortisol paradox
Despite elevated CRF, basal cortisol levels in PTSD patients are typically normal or low. This is the opposite of what the standard stress model predicts. If CRF is elevated, ACTH should be elevated, and cortisol should be elevated. But in many PTSD patients, the downstream hormones do not follow.
The leading explanation is enhanced glucocorticoid negative feedback sensitivity. PTSD patients appear to have increased glucocorticoid receptor (GR) density or sensitivity, meaning that even small amounts of cortisol exert strong suppressive effects on CRF and ACTH release. Dexamethasone suppression tests in PTSD patients typically show enhanced cortisol suppression, the opposite pattern from major depression, where suppression is blunted.
This creates a paradoxical state: the brain is flooded with CRF driving hyperarousal and anxiety, but the peripheral cortisol response is dampened. The system is simultaneously overactive centrally and underactive peripherally.
Blunted acute stress reactivity
When PTSD patients are exposed to standardized laboratory stressors, their cortisol response is often blunted compared to healthy controls. Their HPA axis has partially lost its ability to mount an appropriate acute response. In contrast, exposure to trauma-specific cues (sounds, images, or contexts associated with the original trauma) can produce exaggerated cortisol responses, suggesting the system is not generally suppressed but selectively dysregulated.
CRF Receptor Antagonists: Why They Failed
The elevated CRF in PTSD made CRF1 receptor antagonism an obvious therapeutic target. If CRF1 activation drives anxiety and hyperarousal, blocking CRF1 should reduce PTSD symptoms. Preclinical studies in rodents strongly supported this hypothesis: CRF1 receptor antagonists consistently reduced anxiety-like behavior in animal models of chronic stress.
Multiple pharmaceutical companies developed CRF1 antagonists and brought them to clinical trials. The most definitive result came from a Phase II trial of GSK561679, a CRF1 receptor antagonist tested in 128 women with PTSD. The drug showed no superiority over placebo on the primary outcome measure (Clinician-Administered PTSD Scale total score).
The failure pattern extended beyond PTSD. CRF1 antagonists also failed in clinical trials for major depressive disorder, generalized anxiety disorder, and social anxiety disorder. No CRF1 antagonist has advanced to Phase III for any psychiatric indication.
Several explanations have been proposed. CRF acts through distributed brain circuits, and blocking one receptor subtype may be insufficient. CRF2 receptors, which are thought to promote stress recovery, may partially compensate. Kovács et al. (2025) showed that CRF and the related peptides urocortin 1, 2, and 3 all modulate serotonin release from the raphe nuclei, suggesting that the CRF system's influence on mood extends through multiple neurotransmitter systems that a single receptor antagonist cannot fully address.[4]
Vidal et al. (2025) reviewed the emerging metabolic roles of CRH receptor 2 and its urocortin peptide ligands, suggesting these may be therapeutic targets for metabolic rather than psychiatric conditions, redirecting CRF research toward different indications.[6]
Neuropeptide Y: The Resilience Factor
While CRF drives the stress response, neuropeptide Y (NPY) appears to buffer it. NPY is a 36-amino-acid peptide widely distributed in the brain, with particularly high concentrations in the amygdala and hypothalamus. It acts as an endogenous anxiolytic, counterbalancing CRF's activating effects.
Kautz et al. (2017) reviewed NPY in the context of resilience and PTSD therapeutics in Neuroscience Letters. Military studies have found that soldiers with higher NPY levels during high-stress training (such as prisoner-of-war simulations) show less psychological distress and better performance. PTSD patients, conversely, tend to have reduced NPY levels.[3]
Sabban and Serova (2018) explored the potential of intranasal NPY, alone or combined with melanocortin 4 receptor (MC4R) antagonists, for preventing or treating PTSD. In Military Medicine, they reported that intranasal NPY delivery in rodent models reduced anxiety-like behavior and stress-related neuroendocrine changes, providing a rationale for human trials.[7]
Yerraguntla et al. (2025) mapped the subcellular interactions of NPY and CRF in the central nucleus of the amygdala, the brain region most directly involved in fear conditioning. They found that NPY and CRF fibers converge on the same neuronal populations, suggesting that the balance between these two peptides at specific synapses determines the amygdala's output to downstream fear and arousal circuits.[5]
Singanwad et al. (2025) reviewed NPY's multifaceted role in neuroplasticity, neuroinflammation, and HPA axis dysregulation, with specific attention to treatment-resistant depression. Their analysis in Neuropeptides positioned NPY not just as a stress resilience factor but as a modulator of the inflammatory and neuroplastic processes that perpetuate mood disorders.[8]
The connection between NPY and stress resilience has generated interest in developing NPY-based therapeutics, though the peptide's inability to cross the blood-brain barrier has limited delivery options to intranasal administration and direct CNS delivery.
Other Peptide Players in PTSD HPA Dysregulation
ACTH fragments
ACTH itself is a 39-amino-acid peptide, but several of its fragments have independent biological activity. The ACTH(4-10) fragment has neuroprotective and nootropic properties that are distinct from ACTH's adrenal-stimulating effects.
Inozemtseva et al. (2024) tested two ACTH(4-10) analogs, Semax and Melanotan II, in a chronic unpredictable stress model in male rats. Published in the European Journal of Pharmacology, they found antidepressant-like and antistress effects, suggesting that ACTH-derived peptides can influence stress-related behavior through mechanisms independent of cortisol production.[9]
Glazova et al. (2021) showed that Semax, a synthetic ACTH(4-10) analog, attenuated behavioral and neurochemical alterations following early-life stress exposure in rats, published in Neuropeptides.[10]
Oxytocin
The hypothalamic peptide oxytocin has been studied as an adjunct to exposure therapy for PTSD. Flanagan et al. (2018) conducted a randomized, placebo-controlled pilot trial of intranasal oxytocin combined with Prolonged Exposure therapy in PTSD patients. Published in the Journal of Psychiatric Research, the study found that oxytocin-augmented therapy produced greater reductions in PTSD symptoms than placebo-augmented therapy, though the sample size was small and the findings are preliminary.[11]
Why This Matters for Treatment Development
The HPA axis in PTSD is not simply overactive or underactive. It is reorganized. CRF is elevated centrally while cortisol is suppressed peripherally. Glucocorticoid receptors are upregulated, creating enhanced negative feedback. NPY, which normally counterbalances CRF, is depleted. The amygdala receives excessive CRF input and insufficient NPY input.
This complexity explains why single-target pharmaceutical approaches have struggled. CRF1 antagonism was a logical first attempt, but it failed because the dysfunction involves multiple peptide systems interacting across distributed brain circuits. The emerging direction in research is toward restoring balance between activating peptides (CRF) and inhibiting peptides (NPY), rather than simply blocking one pathway.
Whether through intranasal NPY, oxytocin-augmented psychotherapy, ACTH fragment analogs, or yet-to-be-discovered approaches, the peptide-based understanding of PTSD's neurobiology is providing new frameworks for intervention. The search for peptide biomarkers that can identify HPA axis dysregulation patterns before symptoms become chronic represents another avenue where this research may have practical impact.
The Bottom Line
PTSD disrupts the HPA axis peptide cascade at every level. CRF is chronically elevated in the brain, driving hyperarousal and anxiety through both classical HPA pathways and direct amygdala circuits. Cortisol is paradoxically low due to enhanced glucocorticoid receptor sensitivity. CRF1 receptor antagonists, despite strong preclinical rationale, have failed in human clinical trials. NPY, the endogenous counter-regulatory peptide to CRF, is depleted in PTSD and is being studied as a therapeutic target through intranasal delivery. The HPA axis in PTSD represents not a simple malfunction but a reorganization of peptide signaling that will likely require multi-target approaches to address.